KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma

被引：0
作者：
Boshi Wang
Tiantian Jing
Weilin Jin
Jinnan Chen
Chengsi Wu
Mingrong Wang
Yizhen Liu
机构：
[1] Shanghai Cancer Institute,State Key Laboratory of Oncogenes and Related Genes
[2] Renji Hospital,Institute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education
[3] Shanghai Jiao Tong University School of Medicine,State Key Laboratory of Molecular Oncology, Center for Cancer Precision Medicine
[4] School of Electronic Information and Electronic Engineering,Department of Medical Oncology
[5] Shanghai Jiaotong University,Department of Oncology
[6] Renji Hospital,undefined
[7] School of Medicine,undefined
[8] Shanghai Jiao Tong University,undefined
[9] Shanghai Institute of Digestive Disease,undefined
[10] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,undefined
[11] Chinese Academy of Medical Sciences,undefined
[12] Peking Union Medical College,undefined
[13] Fudan University Shanghai Cancer Center,undefined
[14] Shanghai Medical College,undefined
[15] Fudan University,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 39卷
关键词：
KIAA1522; Lung adenocarcinoma; NFκB; Chemoresistance; Platinum-based chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 198 条
[1]  
Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30
[2]  
Miller KD(2018)The biology and management of non-small cell lung cancer Nature. 553 446-454
[3]  
Jemal A(2018)Toward innovative combinational immunotherapy: a systems biology perspective Cancer Treat Rev 68 1-8
[4]  
Herbst RS(2019)The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer Ther Adv Med Oncol 11 1758835919870360-51
[5]  
Morgensztern D(2016)The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer J Thorac Oncol 11 39-3515
[6]  
Boshoff C(2017)Systemic therapy for stage IV non-small-cell lung Cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 35 3484-363
[7]  
Li XT(2020)Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer Cochrane Database Syst Rev 1 CD009256-50
[8]  
Yang JJ(2007)Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience Lung Cancer 55 357-134
[9]  
Wu YL(2016)Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer Cancer Treat Rev 44 42-465
[10]  
Hou J(2008)Nuclear factor-kappa B as a resistance factor to platinum-based Antineoplasic drugs Met Based Drugs 2008 576104-57
12345678910